Advertisement

Management of Psychiatric Symptoms in Dementia

  • Yavuz Ayhan
    Correspondence
    Corresponding author. Department of Psychiatry, Hacettepe University Faculty of Medicine, 06230, Sihhiye/ Altindag/ Ankara, Turkey.
    Affiliations
    Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA

    Global Brain Health Institute, University of California, San Francisco (UCSF), 1651 4th St, 3rd Floor, San Francisco, CA 94143, USA

    Trinity College Dublin, Dublin, Ireland

    Department of Psychiatry, Hacettepe University Faculty of Medicine, 06230, Sihhiye/ Altindag/ Ankara, Turkey
    Search for articles by this author
  • Selam A. Yoseph
    Affiliations
    Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA

    Global Brain Health Institute, University of California, San Francisco (UCSF), 1651 4th St, 3rd Floor, San Francisco, CA 94143, USA

    Trinity College Dublin, Dublin, Ireland

    Department of Psychiatry, Addis Ababa University, Addis Ababa, Ethiopia
    Search for articles by this author
  • Bruce L. Miller
    Affiliations
    Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA

    Global Brain Health Institute, University of California, San Francisco (UCSF), 1651 4th St, 3rd Floor, San Francisco, CA 94143, USA

    Trinity College Dublin, Dublin, Ireland
    Search for articles by this author
Published:October 17, 2022DOI:https://doi.org/10.1016/j.ncl.2022.05.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Neurologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zhao Q.-F.
        • Tan L.
        • Wang H.-F.
        • et al.
        The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis.
        J Affect Disord. 2016; 190: 264-271
        • Leung D.K.Y.
        • Chan W.C.
        • Spector A.
        • et al.
        Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis.
        Int J Geriatr Psychiatry. 2021; 36: 1330-1344
        • Eikelboom W.S.
        • van den Berg E.
        • Singleton E.H.
        • et al.
        Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations.
        Neurology. 2021; 97: e1276-e1287
        • Ismail Z.
        • Gatchel J.
        • Bateman D.R.
        • et al.
        Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria.
        Int Psychogeriatr. 2018; 30: 185-196
        • Bateman D.R.
        • Gill S.
        • Hu S.
        • et al.
        Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.
        Alzheimers Dement (N Y). 2020; 6: e12016
        • Gerlach L.B.
        • Kales H.C.
        Managing behavioral and psychological symptoms of dementia.
        Psychiatr Clin North Am. 2018; 41: 127-139
        • Peters M.E.
        • Schwartz S.
        • Han D.
        • et al.
        Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study.
        Am J Psychiatry. 2015; 172: 460-465
        • Toot S.
        • Swinson T.
        • Devine M.
        • et al.
        Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis.
        Int Psychogeriatr. 2017; 29: 195-208
        • Matsuoka T.
        • Manabe T.
        • Akatsu H.
        • et al.
        Factors influencing hospital admission among patients with autopsy-confirmed dementia.
        Psychogeriatrics. 2019; 19: 255-263
        • Liu S.
        • Liu J.
        • Wang X.-D.
        • et al.
        Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer’s disease.
        Int Psychogeriatr. 2018; 30: 1131-1138
        • Angeles R.C.
        • Berge L.I.
        • Gedde M.H.
        • et al.
        Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD).
        Health Econ Rev. 2021; 11: 37
        • Burley C.V.
        • Livingston G.
        • Knapp M.R.J.
        • et al.
        Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia.
        Int Psychogeriatr. 2020; 31: 1-6
        • van der Linde R.M.
        • Stephan B.C.M.
        • Dening T.
        • et al.
        Instruments to measure behavioural and psychological symptoms of dementia.
        Int J Methods Psychiatr Res. 2014; 23: 69-98
        • Cummings J.
        The neuropsychiatric inventory: development and applications.
        J Geriatr Psychiatry Neurol. 2020; 33: 73-84
        • Reisberg B.
        • Monteiro I.
        • Torossian C.
        • et al.
        The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.
        Dement Geriatr Cogn Disord. 2014; 38: 89-146
        • Kales H.C.
        Common sense: addressed to geriatric psychiatrists on the subject of behavioral and psychological symptoms of dementia.
        Am J Geriatr Psychiatry. 2015; 23: 1209-1213
        • Seritan A.L.
        • Rienas C.
        • Duong T.
        • et al.
        Ages at onset of anxiety and depressive disorders in parkinson’s disease.
        J Neuropsychiatry Clin Neurosci. 2019; 31: 346-352
        • Rascovsky K.
        • Hodges J.R.
        • Knopman D.
        • et al.
        Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.
        Brain. 2011; 134: 2456-2477
        • Kales H.C.
        • Gitlin L.N.
        • Lyketsos C.G.
        Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel.
        J Am Geriatr Soc. 2014; 62: 762-769
        • Lichtwarck B.
        • Selbaek G.
        • Kirkevold Ø.
        • et al.
        Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: A cluster randomized controlled trial.
        Am J Geriatr Psychiatry. 2018; 26: 25-38
        • Hsu T.-J.
        • Tsai H.-T.
        • Hwang A.-C.
        • et al.
        Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia.
        Geriatr Gerontol Int. 2017; 17: 28-35
        • Vasudev A.
        • Shariff S.Z.
        • Liu K.
        • et al.
        Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013.
        Am J Geriatr Psychiatry. 2015; 23: 1259-1269
        • Campbell N.
        • Ayub A.
        • Boustani M.A.
        • et al.
        Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysis.
        Clin Interv Aging. 2008; 3: 719-728
        • Kishi T.
        • Matsunaga S.
        • Oya K.
        • et al.
        Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis.
        J Alzheimers Dis. 2017; 60: 401-425
        • Tsoi K.K.F.
        • Chan J.Y.C.
        • Leung N.W.Y.
        • et al.
        Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials.
        J Am Med Dir Assoc. 2016; 17: 863.e1-863.e8
        • Brenowitz W.D.
        • Zeki Al Hazzouri A.
        • Vittinghoff E.
        • et al.
        Depressive symptoms imputed across the life course are associated with cognitive impairment and cognitive decline.
        J Alzheimers Dis. 2021; 83: 1379-1389
        • Ly M.
        • Karim H.T.
        • Becker J.T.
        • et al.
        Late-life depression and increased risk of dementia: a longitudinal cohort study.
        Transl Psychiatry. 2021; 11: 147
        • Lee A.T.C.
        • Fung A.W.T.
        • Richards M.
        • et al.
        Risk of incident dementia varies with different onset and courses of depression.
        J Affect Disord. 2021; 282: 915-920
        • Grinberg L.T.
        • Rüb U.
        • Ferretti R.E.L.
        • et al.
        The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?.
        Neuropathol Appl Neurobiol. 2009; 35: 406-416
        • Robinson A.C.
        • Roncaroli F.
        • Davidson Y.S.
        • et al.
        Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer’s disease pathology at death.
        Int J Geriatr Psychiatry. 2021; 36: 713-721
        • Kazmi H.
        • Walker Z.
        • Booij J.
        • et al.
        Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study.
        J Neurol Neurosurg Psychiatr. 2021; 92: 158-164
        • Tay K.-W.
        • Subramaniam P.
        • Oei T.P.
        Cognitive behavioural therapy can be effective in treating anxiety and depression in persons with dementia: a systematic review.
        Psychogeriatrics. 2019; 19: 264-275
        • Orgeta V.
        • Qazi A.
        • Spector A.E.
        • et al.
        Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.
        Cochrane Database Syst Rev. 2014; : CD009125
        • Wang F.L.
        • Tang Q.Y.
        • Zhang L.L.
        • et al.
        Effects of Mindfulness-based Interventions on Dementia Patients: a meta-analysis.
        West J Nurs Res. 2020; 42: 1163-1173
        • Baruch N.
        • Burgess J.
        • Pillai M.
        • et al.
        Treatment for depression comorbid with dementia.
        Evid Based Ment Health. 2019; 22: 167-171
        • Watt J.A.
        • Goodarzi Z.
        • Veroniki A.A.
        • et al.
        Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis.
        BMJ. 2021; 372: n532
        • Kolberg E.
        • Hjetland G.J.
        • Thun E.
        • et al.
        The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial.
        BMC Psychiatry. 2021; 21: 377
        • Orgeta V.
        • Tabet N.
        • Nilforooshan R.
        • et al.
        Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis.
        J Alzheimers Dis. 2017; 58: 725-733
        • Dudas R.
        • Malouf R.
        • McCleery J.
        • et al.
        Antidepressants for treating depression in dementia.
        Cochrane Database Syst Rev. 2018; 8: CD003944
        • Hsu T.-W.
        • Stubbs B.
        • Liang C.-S.
        • et al.
        Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis.
        Ageing Res Rev. 2021; 69: 101362
        • Lebert F.
        • Stekke W.
        • Hasenbroekx C.
        • et al.
        Frontotemporal dementia: a randomised, controlled trial with trazodone.
        Dement Geriatr Cogn Disord. 2004; 17: 355-359
        • Sommerlad A.
        • Werbeloff N.
        • Perera G.
        • et al.
        Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data.
        Int J Geriatr Psychiatry. 2021; 25https://doi.org/10.1002/gps.5625
        • Zuidersma M.
        • Chua K.-C.
        • Hellier J.
        • et al.
        • HTA-SADD Investigator Group
        Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
        Am J Geriatr Psychiatry. 2019; 27: 920-931
        • Karlsson I.
        • Godderis J.
        • Augusto De Mendonça Lima C.
        • et al.
        A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.
        Int J Geriatr Psychiatry. 2000; 15: 295-305
        • de Vasconcelos Cunha U.G.
        • Lopes Rocha F.
        • Avila de Melo R.
        • et al.
        A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia.
        Dement Geriatr Cogn Disord. 2007; 24: 36-41
        • Oslin D.W.
        • Ten Have T.R.
        • Streim J.E.
        • et al.
        Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.
        J Clin Psychiatry. 2003; 64: 875-882
        • Cumbo E.
        • Cumbo S.
        • Torregrossa S.
        • et al.
        Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’s disease patients with depressive symptoms: a 12 month, open-label, observational study.
        J Prev Alzheimers Dis. 2019; 6: 192-197
        • Bobo W.V.
        • Grossardt B.R.
        • Lapid M.I.
        • et al.
        Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population.
        Pharmacol Res Perspect. 2019; 7: e00461
        • Mendez M.F.
        The relationship between anxiety and alzheimer’s disease.
        J Alzheimers Dis Rep. 2021; 5: 171-177
        • Porter V.R.
        • Buxton W.G.
        • Fairbanks L.A.
        • et al.
        Frequency and characteristics of anxiety among patients with Alzheimer’s disease and related dementias.
        J Neuropsychiatry Clin Neurosci. 2003; 15: 180-186
        • Dimitriou T.-D.
        • Verykouki E.
        • Papatriantafyllou J.
        • et al.
        Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial.
        Behav Brain Res. 2020; 390: 112617
        • van der Steen J.T.
        • Smaling H.J.
        • van der Wouden J.C.
        • et al.
        Music-based therapeutic interventions for people with dementia.
        Cochrane Database Syst Rev. 2018; 7: CD003477
        • Jin J.W.
        • Nowakowski S.
        • Taylor A.
        • et al.
        Cognitive behavioral therapy for mood and insomnia in persons with dementia: A systematic review.
        Alzheimer Dis Assoc Disord. 2021; 35: 366-373
        • Santa Cruz M.R.
        • Hidalgo P.C.
        • Lee M.S.
        • et al.
        Buspirone for the treatment of dementia with behavioral disturbance.
        Int Psychogeriatr. 2017; 29: 859-862
        • Marston L.
        • Livingston G.
        • Laybourne A.
        • et al.
        Becoming or remaining agitated: the course of agitation in people with dementia living in care homes. The english longitudinal managing agitation and raising quality of life (MARQUE) study.
        J Alzheimers Dis. 2020; 76: 467-473
        • Vik-Mo A.O.
        • Giil L.M.
        • Borda M.G.
        • et al.
        The individual course of neuropsychiatric symptoms in people with Alzheimer’s and Lewy body dementia: 12-year longitudinal cohort study.
        Br J Psychiatry. 2020; 216: 43-48
        • Leng M.
        • Zhao Y.
        • Wang Z.
        Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis.
        Int J Nurs Stud. 2020; 102: 103489
        • Watt J.A.
        • Goodarzi Z.
        • Veroniki A.A.
        • et al.
        Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis.
        Ann Intern Med. 2019; 171: 633-642
        • Weintraub D.
        • Drye L.T.
        • Porsteinsson A.P.
        • et al.
        Time to response to citalopram treatment for agitation in Alzheimer disease.
        Am J Geriatr Psychiatry. 2015; 23: 1127-1133
        • Viscogliosi G.
        • Chiriac I.M.
        • Ettorre E.
        Efficacy and safety of citalopram compared to atypical antipsychotics on agitation in nursing home residents with alzheimer dementia.
        J Am Med Dir Assoc. 2017; 18: 799-802
        • Newell J.
        • Yesavage J.A.
        • Taylor J.L.
        • et al.
        Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease.
        J Psychiatr Res. 2016; 74: 17-21
        • Banerjee S.
        • High J.
        • Stirling S.
        • et al.
        Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2021; 398: 1487-1497
        • Frederiksen K.S.
        • Cooper C.
        • Frisoni G.B.
        • et al.
        A European Academy of Neurology guideline on medical management issues in dementia.
        Eur J Neurol. 2020; 27: 1805-1820
        • Aigbogun M.S.
        • Cloutier M.
        • Gauthier-Loiselle M.
        • et al.
        Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review.
        J Alzheimers Dis. 2020; 77: 1181-1194
        • Kongpakwattana K.
        • Sawangjit R.
        • Tawankanjanachot I.
        • et al.
        Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
        Br J Clin Pharmacol. 2018; 84: 1445-1456
      1. Schedule of Pharmaceutical Benefits, General Pharmaceutical Schedule - Volume 1, published by: Australian Government, Department of Health. Canberra, Commonwealth of Australia.January 2022. Available at: https://www.pbs.gov.au/publication/schedule/2022/07/2022-07-01-general-%20schedule-volume-1.pdf.

        • Committee for Medicinal Products for Human Use (CHMP)
        Opinion following an article 30 referral for risperdal and associated names.
        European Medicines Agency, London2008
      2. Risperidone - Restriction of the Dementia Indication - Recalls and safety alerts.
        (Available at:) (Accessed January 18, 2022)
        • Mintzer J.E.
        • Tune L.E.
        • Breder C.D.
        • et al.
        Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
        Am J Geriatr Psychiatry. 2007; 15: 918-931
        • Devanand D.P.
        • Crocco E.
        • Forester B.P.
        • et al.
        Low dose lithium treatment of behavioral complications in Alzheimer’s disease: lit-AD randomized clinical trial.
        Am J Geriatr Psychiatry. 2021; https://doi.org/10.1016/j.jagp.2021.04.014
        • Stella F.
        • Valiengo L.C.L.
        • de Paula V.J.R.
        • et al.
        Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review.
        Trends Psychiatry Psychother. 2021; https://doi.org/10.47626/2237-6089-2021-0288
        • Ballard C.G.
        • Coate B.
        • Abler V.
        • et al.
        Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis.
        Int J Geriatr Psychiatry. 2020; 35: 1402-1408https://doi.org/10.1002/gps.5381
        • Cummings J.L.
        • Lyketsos C.G.
        • Peskind E.R.
        • et al.
        Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial.
        JAMA. 2015; 314: 1242-1254
        • Watt J.A.
        • Goodarzi Z.
        • Veroniki A.A.
        • et al.
        Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis.
        BMC Geriatr. 2020; 20: 212
        • Tariot P.N.
        • Erb R.
        • Podgorski C.A.
        • et al.
        Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
        Am J Psychiatry. 1998; 155: 54-61
        • Liu K.Y.
        • Borissova A.
        • Mahmood J.
        • et al.
        Pharmacological treatment trials of agitation in Alzheimer’s disease: a systematic review of ClinicalTrials.gov registered trials.
        Alzheimers Dement (N Y). 2021; 7: e12157
        • Chen J.
        • Bell S.
        • Brain C.
        The incidence of dementia-related psychosis in people with dementia: Results from a survey of 302 U.S. healthcare providers.
        Alzheimers Dement. 2020; 16https://doi.org/10.1002/alz.047138
        • Vilalta-Franch J.
        • López-Pousa S.
        • Calvó-Perxas L.
        • et al.
        Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality.
        Am J Geriatr Psychiatry. 2013; 21: 1135-1143
        • Maust D.T.
        • Kim H.M.
        • Seyfried L.S.
        • et al.
        Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
        JAMA Psychiatry. 2015; 72: 438-445
        • Yeh T.-C.
        • Tzeng N.-S.
        • Li J.-C.
        • et al.
        Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials.
        J Clin Psychopharmacol. 2019; 39: 472-478
        • Ballard C.
        • Hanney M.L.
        • Theodoulou M.
        • et al.
        The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
        Lancet Neurol. 2009; 8: 151-157
        • APA
        Five things physicians and patients should question.
        American Psychiatric Association Choosing wisely, Philadelphia, PA2013
      3. American Geriatrics Society | Choosing Wisely.
        (Available at:) (Accessed January 3, 2022)
        • Ballard C.
        Evidence-based treatment and monitoring strategies for dementia-related psychosis.
        J Clin Psychiatry. 2021; 82https://doi.org/10.4088/JCP.AD19038BR4C
        • Yunusa I.
        • Rashid N.
        • Abler V.
        • et al.
        Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review.
        J Prev Alzheimers Dis. 2021; 8: 520-533
        • Yunusa I.
        • Alsumali A.
        • Garba A.E.
        • et al.
        Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.
        JAMA Netw Open. 2019; 2: e190828
        • Mühlbauer V.
        • Möhler R.
        • Dichter M.N.
        • et al.
        Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia.
        Cochrane Database Syst Rev. 2021; 12: CD013304
        • Ballard C.
        • Banister C.
        • Khan Z.
        • et al.
        Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
        Lancet Neurol. 2018; 17: 213-222
        • Tariot P.N.
        • Cummings J.L.
        • Soto-Martin M.E.
        • et al.
        Trial of Pimavanserin in Dementia-Related Psychosis.
        N Engl J Med. 2021; 385: 309-319
        • The Lancet Neurology
        Difficult choices in treating Parkinson’s disease psychosis.
        Lancet Neurol. 2018; 17: 569
        • Naasan G.
        • Shdo S.M.
        • Rodriguez E.M.
        • et al.
        Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms.
        Brain. 2021; 144: 999-1012
        • Badwal K.
        • Kiliaki S.A.
        • Dugani S.B.
        • et al.
        Psychosis management in lewy body dementia: A comprehensive clinical approach.
        J Geriatr Psychiatry Neurol. 2021; 19https://doi.org/10.1177/0891988720988916
        • Kyle K.
        • Bronstein J.M.
        Treatment of psychosis in Parkinson’s disease and dementia with Lewy Bodies: a review.
        Parkinsonism Relat Disord. 2020; 75: 55-62
        • Taylor J.-P.
        • McKeith I.G.
        • Burn D.J.
        • et al.
        New evidence on the management of Lewy body dementia.
        Lancet Neurol. 2020; 19: 157-169
        • Borges L.G.
        • Rademaker A.W.
        • Bigio E.H.
        • et al.
        Apathy and disinhibition related to neuropathology in amnestic versus behavioral dementias.
        Am J Alzheimers Dis Other Demen. 2019; 34: 337-343
        • Magrath Guimet N.
        • Miller B.L.
        • Allegri R.F.
        • et al.
        What do we mean by behavioral disinhibition in frontotemporal dementia?.
        Front Neurol. 2021; 12: 707799
        • Keszycki R.M.
        • Fisher D.W.
        • Dong H.
        The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer’s disease: current management and future directions.
        Front Pharmacol. 2019; 10: 1109
        • Sarangi A.
        • Jones H.
        • Bangash F.
        • et al.
        Treatment and management of sexual disinhibition in elderly patients with neurocognitive disorders.
        Cureus. 2021; 13: e18463
        • Liljegren M.
        • Naasan G.
        • Temlett J.
        • et al.
        Criminal behavior in frontotemporal dementia and Alzheimer disease.
        JAMA Neurol. 2015; 72: 295-300
        • Trieu C.
        • Gossink F.
        • Stek M.L.
        • et al.
        Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review.
        Cogn Behav Neurol. 2020; 33: 1-15
        • Nisar M.
        • Abubaker Z.J.
        • Nizam M.A.
        • et al.
        Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and meta-analysis.
        Clin Neuropharmacol. 2021; 44: 175-183
        • Hughes L.E.
        • Rittman T.
        • Regenthal R.
        • et al.
        Improving response inhibition systems in frontotemporal dementia with citalopram.
        Brain. 2015; 138: 1961-1975
        • Nagata T.
        • Shinagawa S.
        • Nakajima S.
        • et al.
        Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer’s disease: analysis of the CATIE-AD study.
        J Alzheimers Dis. 2016; 50: 839-845
        • Lee K.S.
        • Kim S.-H.
        • Hwang H.-J.
        Behavioral and Psychological symptoms of dementia and antipsychotic drug use in the elderly with dementia in korean long-term care facilities.
        Drugs Real World Outcomes. 2015; 2: 363-368
        • Nomoto H.
        • Matsubara Y.
        • Ichimiya Y.
        • et al.
        A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole.
        Psychogeriatrics. 2017; 17: 509-510
        • Sarikaya S.
        • Sarikaya B.
        Aripiprazole for the Treatment of inappropriate sexual behavior: case report of an Alzheimer’s disease patient known as heterosexual with recently shifted sexual orientation to same gender.
        J Alzheimers Dis Rep. 2018; 2: 117-121
        • Sherman C.
        • Liu C.S.
        • Herrmann N.
        • et al.
        Prevalence, neurobiology, and treatments for apathy in prodromal dementia.
        Int Psychogeriatr. 2018; 30: 177-184
        • Merrilees J.
        • Dowling G.A.
        • Hubbard E.
        • et al.
        Characterization of apathy in persons with frontotemporal dementia and the impact on family caregivers.
        Alzheimer Dis Assoc Disord. 2013; 27: 62-67
        • Mortby M.E.
        • Adler L.
        • Agüera-Ortiz L.
        • et al.
        Apathy as a treatment target in alzheimer’s disease: implications for clinical trials.
        Am J Geriatr Psychiatry. 2021; https://doi.org/10.1016/j.jagp.2021.06.016
        • Cai Y.
        • Li L.
        • Xu C.
        • et al.
        The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews.
        Worldviews Evid Based Nurs. 2020; 17: 311-318
        • Theleritis C.
        • Siarkos K.
        • Politis A.A.
        • et al.
        A systematic review of non-pharmacological treatments for apathy in dementia.
        Int J Geriatr Psychiatry. 2018; 33: e177-e192
        • Ruthirakuhan M.T.
        • Herrmann N.
        • Abraham E.H.
        • et al.
        Pharmacological interventions for apathy in Alzheimer’s disease.
        Cochrane Database Syst Rev. 2018; 5: CD012197
        • Mintzer J.
        • Lanctôt K.L.
        • Scherer R.W.
        • et al.
        Effect of methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial.
        JAMA Neurol. 2021; 78: 1324-1332
        • Frakey L.L.
        • Salloway S.
        • Buelow M.
        • et al.
        A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease.
        J Clin Psychiatry. 2012; 73: 796-801
        • Takemoto M.
        • Ohta Y.
        • Hishikawa N.
        • et al.
        The efficacy of sertraline, escitalopram, and nicergoline in the treatment of depression and apathy in alzheimer’s disease: the okayama depression and apathy project (ODAP).
        J Alzheimers Dis. 2020; 76: 769-772
        • Zhou T.
        • Wang J.
        • Xin C.
        • et al.
        Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: A clinical trial.
        Exp Ther Med. 2019; 17: 1625-1630
        • Padala P.R.
        • Padala K.P.
        • Majagi A.S.
        • et al.
        Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study.
        Medicine (Baltimore). 2020; 99: e21497
        • Maier F.
        • Spottke A.
        • Bach J.-P.
        • et al.
        Bupropion for the treatment of apathy in alzheimer disease: a randomized clinical trial.
        JAMA Netw Open. 2020; 3: e206027
        • Gelderblom H.
        • Wüstenberg T.
        • McLean T.
        • et al.
        Bupropion for the treatment of apathy in Huntington’s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
        PLoS One. 2017; 12: e0173872
        • Insel P.S.
        • Mohlenhoff B.S.
        • Neylan T.C.
        • et al.
        Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults.
        JAMA Netw Open. 2021; 4: e2117573https://doi.org/10.1001/jamanetworkopen.2021.17573
        • Ju Y.-E.S.
        • Ooms S.J.
        • Sutphen C.
        • et al.
        Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.
        Brain. 2017; 140: 2104-2111
        • Holth J.K.
        • Fritschi S.K.
        • Wang C.
        • et al.
        The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.
        Science. 2019; 363: 880-884
        • Oh J.
        • Eser R.A.
        • Ehrenberg A.J.
        • et al.
        Profound degeneration of wake-promoting neurons in Alzheimer’s disease.
        Alzheimers Dement. 2019; 15: 1253-1263
        • McKeith I.G.
        • Boeve B.F.
        • Dickson D.W.
        • et al.
        Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.
        Neurology. 2017; 89: 88-100
        • Cassidy-Eagle E.
        • Siebern A.
        • Unti L.
        • et al.
        Neuropsychological functioning in older adults with mild cognitive impairment and insomnia randomized to CBT-I or control group.
        Clin Gerontol. 2018; 41: 136-144
        • Falck R.S.
        • Davis J.C.
        • Best J.R.
        • et al.
        Effect of a Multimodal Lifestyle Intervention on Sleep and Cognitive Function in Older Adults with Probable Mild Cognitive Impairment and Poor Sleep: A Randomized Clinical Trial.
        J Alzheimers Dis. 2020; 76: 179-193
      4. Stages & Behaviors | Alzheimer’s Association.
        (Available at:) (Accessed January 24, 2022)
        • McCleery J.
        • Sharpley A.L.
        Pharmacotherapies for sleep disturbances in dementia.
        Cochrane Database Syst Rev. 2020; 11: CD009178
        • Herring W.J.
        • Ceesay P.
        • Snyder E.
        • et al.
        Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial.
        Alzheimers Dement. 2020; 16: 541-551
        • Wade A.G.
        • Farmer M.
        • Harari G.
        • et al.
        Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial.
        Clin Interv Aging. 2014; 9: 947-961
        • Camargos E.F.
        • Pandolfi M.B.
        • Freitas M.P.D.
        • et al.
        Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study.
        Arq Neuropsiquiatr. 2011; 69: 44-49
        • Camargos E.F.
        • Louzada L.L.
        • Quintas J.L.
        • et al.
        Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study.
        Am J Geriatr Psychiatry. 2014; 22: 1565-1574
        • Scoralick F.M.
        • Louzada L.L.
        • Quintas J.L.
        • et al.
        Mirtazapine does not improve sleep disorders in Alzheimer’s disease: results from a double-blind, placebo-controlled pilot study.
        Psychogeriatrics. 2017; 17: 89-96
        • Abdelhamid A.
        • Bunn D.
        • Copley M.
        • et al.
        Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis.
        BMC Geriatr. 2016; 16: 26
        • Shinagawa S.
        • Honda K.
        • Kashibayashi T.
        • et al.
        Classifying eating-related problems among institutionalized people with dementia.
        Psychiatry Clin Neurosci. 2016; 70: 175-181
        • Ikeda M.
        • Brown J.
        • Holland A.J.
        • et al.
        Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease.
        J Neurol Neurosurg Psychiatr. 2002; 73: 371-376
        • Wu H.-S.
        Predictors of hyperphagia in institutionalized patients with dementia.
        J Nurs Res. 2014; 22: 250-258
        • Chi L.-W.
        • Lin S.-C.
        • Chang S.-H.
        • et al.
        Factors associated with hyperphagic behavior in patients with dementia living at home.
        Biol Res Nurs. 2015; 17: 567-573
        • Kao C.-C.
        • Lin L.-C.
        • Wu S.-C.
        • et al.
        Effectiveness of different memory training programs on improving hyperphagic behaviors of residents with dementia: a longitudinal single-blind study.
        Clin Interv Aging. 2016; 11: 707-720
        • Shinagawa S.
        • Tsuno N.
        • Nakayama K.
        Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate.
        Psychogeriatrics. 2013; 13: 58-61
        • Swartz J.R.
        • Miller B.L.
        • Lesser I.M.
        • et al.
        Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.
        J Clin Psychiatry. 1997; 58: 212-216
        • Lewis C.
        • Walterfang M.
        • Velakoulis D.
        • et al.
        A review: mealtime difficulties following frontotemporal lobar degeneration.
        Dement Geriatr Cogn Disord. 2018; 46: 285-297
        • Rosen H.J.
        • Allison S.C.
        • Ogar J.M.
        • et al.
        Behavioral features in semantic dementia vs other forms of progressive aphasias.
        Neurology. 2006; 67: 1752-1756
      5. Managing Care for Frontotemporal Degeneration (FTD) | AFTD.
        (Available at:) (Accessed January 18, 2022)
        • Benussi A.
        • Premi E.
        • Gazzina S.
        • et al.
        Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia.
        JAMA Netw Open. 2021; 4: e2030194
        • Gambogi L.B.
        • Guimarães H.C.
        • de Souza L.C.
        • et al.
        Treatment of the behavioral variant of frontotemporal dementia: a narrative review.
        Dement Neuropsychol. 2021; 15: 331-338